Our focus in the clinic is on advancing our lead candidate, berberine ursodeoxycholate (HTD1801), in chronic metabolic diseases and liver diseases. Based on its dual mechanism of action we are particularly focused on diseases driven by insulin resistance and chronic inflammation. In addition to our lead candidate, we have a growing discovery portfolio.
HighTide’s mission is to identify the unmet needs in these inter-related chronic metabolic and liver diseases and translate those needs into new therapeutic solutions.
October 15, 2024
HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD’s The Liver Meeting® 2024, Demonstrating Benefits of Berberine Ursodeoxycholate (HTD1801)
September 30, 2024
HighTide Therapeutics to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference
September 19, 2024
8th Annual MASH Drug Development Summit | HighTide Therapeutics Presents Rationales for Holistic Approaches to Treating MASH and Benefits of Berberine Ursodeoxycholate (HTD1801)